How do we respond to the threat of multidrug-resistant bacteria? Comparison of antibiotic appraisals from 2016 to 2020 of the French, English, and German HTA agencies
International Journal of Technology Assessment in Health Care · 2024
DOI: 10.1017/s0266462324000552 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Technology Assessment in Health Care, 2024. Verfasst von Rémy Dumont und 9 weiteren Autor:innen. Beteiligte Einrichtung: Assessment and Access to Innovation Direction, Haute Autorité de Santé, Saint-Denis, France. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antimicrobial resistance (AMR) has become a worldwide growing concern over the past decades. Thus, encouraging manufacturers to develop new antibiotics is needed. We hypothesised that transparency on the regulatory appraisals of antibiotics would provide an incentive to pharmaceutical development. We thus aimed at reporting the French health technology assessment (HTA) opinions and reimbursement decision on antibiotics to those German (G-BA) and English (NICE) HTA bodies. A qualitative analysis of the Transparency Committee of the French National Authority for Health (TC-HAS) opinions regarding antibiotics assessment between 2016 and 2020 was performed. Decisions of reimbursement by TC-HAS were compared to those from G-BA and NICE when available. TC-HAS recognized a clinical benefit (CB) for 15/15 evaluated indications, a clinical added value for 9/15, and a public health interest for 8/15. Among the valued antibiotics by HAS, 5 were recommended for restricted use as a “reserve” to protect against the risk of resistance emergence. A comparison of HTA opinions was possible across HTA for only 8 antibiotics. The G-BA granted a reserve status for 4 drugs and NICE a reserve with restricted use for 5 antibiotics. Three of these antibiotics were positioned similarly by the English, German, and French HTA bodies. This qualitative analysis of HTA opinions between different European HTA bodies shows a consistent reimbursement decision of antibiotics against MDR bacteria and tuberculosis besides the differences in the applied assessment methods. This work also shows how HTA bodies could recognize a clinical added value in a context of the emergence of antibiotic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Assessment and Access to Innovation Direction, Haute Autorité de Santé, Saint-Denis, France.
- Haematology Department, AP-HP Saint Louis Hospital, Paris, France.
- Infectious Diseases, Annecy Genevois Hospital, CHANGE, Annecy, France.
- Department of Infectious Diseases, University Hospital of Brest, Brest, France.
- Service de Médecine Interne, Hôpital Louis-Mourier, Assistance Publique-Hôpitaux de Paris, Colombes, France.
- UPD5, Université Paris-Descartes, Paris, France.
ORCID-Profile: Etienne Lengliné
Zitieren
APA
Dumont, R., Lengliné, E., Delorme, C., Bru, J. P., Ansart, S., Aslangul, E., Kelley, S., Cochat, P., Chevret, S., & Diatta, T. (2024). How do we respond to the threat of multidrug-resistant bacteria? Comparison of antibiotic appraisals from 2016 to 2020 of the French, English, and German HTA agencies. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462324000552
Vancouver
Dumont R, Lengliné E, Delorme C, Bru JP, Ansart S, Aslangul E, et al. How do we respond to the threat of multidrug-resistant bacteria? Comparison of antibiotic appraisals from 2016 to 2020 of the French, English, and German HTA agencies. International Journal of Technology Assessment in Health Care. 2024. doi:10.1017/s0266462324000552
BibTeX
@article{Dumont2024,
author = {Dumont, Rémy and Lengliné, Etienne and Delorme, Clara and Bru, Jean-Pierre and Ansart, Sévérine and Aslangul, Elisabeth and Kelley, Sophie and Cochat, Pierre and Chevret, Sylvie and Diatta, Thierno},
title = {How do we respond to the threat of multidrug-resistant bacteria? Comparison of antibiotic appraisals from 2016 to 2020 of the French, English, and German HTA agencies},
journal = {International Journal of Technology Assessment in Health Care},
year = {2024},
doi = {10.1017/s0266462324000552}
}
EUVIMED